Royal Bank Of Canada began coverage on shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in a research note issued to investors on Thursday, Marketbeat.com reports. The brokerage issued an outperform rating and a $78.00 price target on the biopharmaceutical company’s stock.
Other analysts have also issued research reports about the company. Oppenheimer Holdings, Inc. reaffirmed an outperform rating and issued a $83.00 target price (up previously from $75.00) on shares of Agios Pharmaceuticals in a report on Thursday, August 10th. SunTrust Banks, Inc. reaffirmed a buy rating and issued a $80.00 target price (up previously from $68.00) on shares of Agios Pharmaceuticals in a report on Tuesday, August 8th. Leerink Swann raised Agios Pharmaceuticals from a market perform rating to an outperform rating and raised their target price for the company from $50.00 to $80.00 in a report on Wednesday, August 2nd. Cann reaffirmed a buy rating and issued a $75.00 target price on shares of Agios Pharmaceuticals in a report on Sunday, June 11th. Finally, Janney Montgomery Scott reaffirmed a hold rating on shares of Agios Pharmaceuticals in a report on Tuesday, August 1st. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $75.11.
Agios Pharmaceuticals (NASDAQ AGIO) opened at 66.43 on Thursday. The firm has a 50 day moving average price of $60.25 and a 200-day moving average price of $54.45. The firm’s market capitalization is $3.21 billion. Agios Pharmaceuticals has a 12 month low of $39.24 and a 12 month high of $67.74.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.57) by ($0.21). The business had revenue of $11.30 million during the quarter, compared to analyst estimates of $10.68 million. Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 68.15%. The business’s quarterly revenue was up 62.1% compared to the same quarter last year. During the same period last year, the business earned ($1.47) EPS. On average, equities analysts forecast that Agios Pharmaceuticals will post ($7.07) EPS for the current year.
In related news, insider Scott Biller sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $65.00, for a total transaction of $975,000.00. Following the completion of the transaction, the insider now owns 6,264 shares in the company, valued at approximately $407,160. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Lewis Clayton Jr. Cantley sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $65.47, for a total value of $65,470.00. Following the transaction, the director now owns 86,394 shares of the company’s stock, valued at approximately $5,656,215.18. The disclosure for this sale can be found here. Insiders sold a total of 104,230 shares of company stock valued at $6,245,972 in the last quarter. Corporate insiders own 10.55% of the company’s stock.
Several institutional investors have recently bought and sold shares of AGIO. Bank of Montreal Can lifted its position in shares of Agios Pharmaceuticals by 11.7% during the 1st quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 216 shares during the period. Blue Sky Asset Management LLC bought a new position in shares of Agios Pharmaceuticals during the 1st quarter worth approximately $129,000. QS Investors LLC bought a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth approximately $144,000. Russell Investments Group Ltd. lifted its position in shares of Agios Pharmaceuticals by 163.9% during the 1st quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock worth $149,000 after buying an additional 1,583 shares during the period. Finally, Cubist Systematic Strategies LLC lifted its position in shares of Agios Pharmaceuticals by 1,041.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock worth $176,000 after buying an additional 3,123 shares during the period. Institutional investors and hedge funds own 94.40% of the company’s stock.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.